Dechra

Dechra Targets 2027 for First Ready-to-Use Pet Cell Therapy via Gallant
Dechra has completed its acquisition of biotechnology firm Gallant Pet to integrate off-the-shelf mesenchymal stromal cell therapies into its veterinary portfolio.

Dechra has completed its acquisition of biotechnology firm Gallant Pet to integrate off-the-shelf mesenchymal stromal cell therapies into its veterinary portfolio.
We use cookies to measure readership and, with your permission, to show relevant TechUpscale ads on other sites. We honor Global Privacy Control. You can change your choice any time under "Cookie settings" at the bottom of every page. Privacy policy